Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Drugs with the Active Ingredient Combination Olodaterol and Tiotropium Bromide (Atc: R03al06)

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Fremanezumab, Atc N02cd03 for the Period July 1St, 2023 - June 30Th, 2025

Completion of Non-exclusive Drug Discounts According to Section 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Fusidic Acid/betamethasone (atc Code According to Who: D07cc01)

Medicines Contracts with Accession Option

Drug Contracts with Option to Join

Open House Discount Drug Contracts Sapropterin, Atc A16ax07

Open House Drug Discount Agreements Ferrous Carboxymaltose, Atc B03ac01

Open House Drug Rebate Contracts Lapatinib, Atc L01eh01

Conclusion of Non-Exclusive Discount Agreements According to § 130A Paragraph 8 Sgb V for the Active Ingredient Vedolizumab

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the Active Ingredient Interferon Beta-1A (Avonex(R))